Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (31)

2023

  1. Inhaler Adherence in COPD: A Crucial Step Towards the Correct Treatment

    International journal of chronic obstructive pulmonary disease, Vol. 18, pp. 2887-2893

  2. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

  3. Psychometric properties of the Clarke questionnaire for hypoglycemia awareness in the Spanish population with type 2 diabetes

    Postgraduate Medicine, Vol. 135, Núm. 2, pp. 141-148

2022

  1. ANTES Program: One Year on

    Archivos de Bronconeumologia

  2. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update)

    Revista de Osteoporosis y Metabolismo Mineral, Vol. 14, Núm. 1, pp. 5-12

  3. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

  4. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

    European Journal of Cancer, Vol. 161, pp. 26-37

  5. [Translated article] ANTES Program: One Year on

    Archivos de Bronconeumologia

2021

  1. Predictors of adoption and impact of evidence-based programming on the incidence of implantable cardioverter-defibrillator therapies

    Revista Espanola de Cardiologia, Vol. 74, Núm. 4, pp. 296-302

  2. Recommendations for ophthalmologic practice during the easing of COVID-19 control measures

    Acta Ophthalmologica, Vol. 99, Núm. 7, pp. e973-e983

  3. The role of bronchoscopy in patients with sars-cov-2 pneumonia

    ERJ Open Research, Vol. 7, Núm. 3

2020

  1. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

    Breast Cancer Research, Vol. 22, Núm. 1

  2. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)

    Breast, Vol. 54, pp. 286-292

  3. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2019

  1. Spanish Results of the Second European Cardiac Resynchronization Therapy Survey (CRT-Survey II)

    Revista Espanola de Cardiologia, Vol. 72, Núm. 12, pp. 1020-1030

2018

  1. Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers

    Annals of Oncology, Vol. 29, pp. ix24

  2. Dalbavancin in the treatment of different gram-positive infections: a real-life experience

    International Journal of Antimicrobial Agents, Vol. 51, Núm. 4, pp. 571-577

  3. Position statement for the management of comorbidities in psoriasis

    Journal of the European Academy of Dermatology and Venereology, Vol. 32, Núm. 12, pp. 2058-2073

2017

  1. Nonfluoroscopic Catheter Ablation. Results From a Prospective Multicenter Registry

    Revista Espanola de Cardiologia, Vol. 70, Núm. 9, pp. 699-705

2016

  1. Long-term adherence to IFN beta-1a treatment when using rebismart1device in patients with relapsing-remitting multiple sclerosis

    PLoS ONE, Vol. 11, Núm. 8